Solventum (SOLV) Q2 2024 earnings summary

Executive summary

• Completed spin-off from 3M on April 1, 2024, becoming an independent public company listed on the NYSE, with business continuity maintained and early progress on transformation initiatives.

• Q2 2024 net sales were $2.081 billion, up 0.2% year-over-year reported and 1.3% organic, reflecting normalized pricing and slight volume growth.

• Adjusted EPS was $1.56, including a full quarter of interest expense; GAAP EPS was $0.51; net income was $89 million, down from $321 million in Q2 2023.

• Transformation and talent acquisition initiatives are ahead of schedule, supporting faster strategic planning.

• The company operates in four segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Financial highlights

• Q2 2024 net sales: $2.081 billion (+0.2% reported, +1.3% organic); adjusted operating income: $430 million (20.7% margin); GAAP operating income: $244 million (11.7% margin).

• Gross margin for Q2 2024 was 54.6% (GAAP) and 55.8% (adjusted), both down year-over-year due to higher costs and unfavorable mix.

• Q2 2024 net income: $89 million; free cash flow: $297 million; cash from operations: $355 million.

• Q2 2024 interest expense was $114 million, reflecting new standalone company costs.

• Ended Q2 2024 with $897 million in cash and $8.3 billion in long-term debt.

Outlook and guidance

• Full-year 2024 organic sales growth guidance raised to 0%–1%; adjusted EPS guidance increased to $6.30–$6.50; free cash flow expected at $700–$800 million.

• Adjusted effective tax rate now expected at 18%–19%, a temporary benefit from geographic income mix.

• 3M supply agreement mark-up to impact income statement starting Q3 2024.

• SKU rationalization project underway, not expected to materially impact 2024 revenue or margin.

• Standalone costs and higher interest expense from new debt are expected to continue affecting profitability.